 |
|
|
 |
Drug Watch: Investigational Agent, Etoricoxib, Caused Less GI Damage Than Ibuprofen In New Study
A new study showed an investigational pain and arthritis medicine, etoricoxib, caused significantly less gastrointestinal (GI) blood loss -- an indicator of GI damage -- than the non-selective, non-steroidal anti-inflammatory drug (NSAID) ibuprofen and was equivalent to placebo. more
|
|
Inhaled Antisense Oligonucleotides Show Promise In Tackling Multifaceted Diseases
Research presented by scientists from EpiGenesis of Cranbury, NJ, indicates a new class of drugs may offer improved control of multifactorial diseases by targeting multiple mRNAs simultaneously. The class of drugs being studied is respirable antisense oligonucleotides (RASONs), pioneered by EpiGenesis. Multifactorial diseases include asthma, chronic obstructive pulmonary diseases and many cancers. more
|
|
|
|
Identification Of Stroke Gene And Location Of Gene Linked To Type 2 Diabetes Announced
deCODE genetics and Roche Pharmaceuticals have announced two new accomplishments that characterize the genetic factors contributing to important common diseases. deCODE scientists have identified a gene causally involved in cerebrovascular disease, or stroke, and have mapped the chromosomal location of a gene linked to type 2 diabetes. more
|
|
Long-Term Remissions In Crohn's Disease Possible With Infliximab
Periodic treatment with the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease, a multi-center research team reports today at the Digestive Disease Week meeting in Atlanta. more
|
|
Ezetimibe, An Investigational Cholesterol Absorption Inhibitor, Reduces Low-Density Lipoprotein Cholesterol (LDL-C) Levels
Ezetimibe, an investigational cholesterol absorption inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) levels, the so-called quot;bad" cholesterol, by 18 percent and total cholesterol (TC) by 12 percent, in a new Phase III study presented yesterday at the European Atherosclerosis Society Meeting. more
|
|
|
